posted on 2024-06-11, 23:43authored byInés Álvarez-Miguel, Beatrice Fodor, Guillermo G. López, Catalina Biglione, Erik Svensson Grape, A. Ken Inge, Tania Hidalgo, Patricia Horcajada
The SARS-CoV-2 (COVID-19) pandemic outbreak led to enormous
social
and economic repercussions worldwide, felt even to this date, making
the design of new therapies to combat fast-spreading viruses an imperative
task. In the face of this, diverse cutting-edge nanotechnologies have
risen as promising tools to treat infectious diseases such as COVID-19,
as well as challenging illnesses such as cancer and diabetes. Aside
from these applications, nanoscale metal–organic frameworks
(nanoMOFs) have attracted much attention as novel efficient drug delivery
systems for diverse pathologies. However, their potential as anti-COVID-19
therapeutic agents has not been investigated. Herein, we propose a
pioneering anti-COVID MOF approach by studying their potential as
safe and intrinsically antiviral agents through screening various
nanoMOF. The iron(III)-trimesate MIL-100 showed a noteworthy antiviral
effect against SARS-CoV-2 at the micromolar range, ensuring a high
biocompatibility profile (90% of viability) in a real infected human
cellular scenario. This research effectively paves the way toward
novel antiviral therapies based on nanoMOFs, not only against SARS-CoV-2
but also against other challenging infectious and/or pulmonary diseases.